TABLE 3.
Correlation between SIRI and chemotherapy.
| Parameters | Low SIRI <1.21 | High SIRI ≥1.21 | χ2 | P Value | |
|---|---|---|---|---|---|
| Cases (n) | Number (%) | 62 | 45 | ||
| NACT regimens | |||||
| SOX | 35 (32.7%) | 17 (27.4%) | 18 (40.0%) | 7.151 | 0.028 |
| XELOX | 56 (52.3%) | 39 (62.9%) | 17 (37.8%) | ||
| Others a | 16 (15.0%) | 6 (9.7%) | 10 (22.2%) | ||
| Preoperative chemotherapy times | |||||
| <3 | 57 (53.3%) | 38 (61.3%) | 19 (42.2%) | 3.809 | 0.051 |
| ≥3 | 50 (46.7%) | 24 (38.7%) | 26 (57.8%) | ||
| Postoperative chemotherapy regimens | |||||
| SOX | 32 (29.9%) | 16 (25.8%) | 16 (35.5%) | 2.103 | 0.717 |
| XELOX | 41 (38.3%) | 26 (41.9%) | 15 (33.3%) | ||
| Others a | 20 (18.7%) | 13 (21.0%) | 7 (15.6%) | ||
| No | 14 (13.1%) | 7 (11.3%) | 7 (15.6%) | ||
| Postoperative chemotherapy times | |||||
| 0 | 14 (13.1%) | 7 (11.3%) | 7 (15.6%) | 2.198 | 0.333 |
| <4 | 51 (47.7%) | 27 (43.5%) | 24 (53.3%) | ||
| ≥4 | 42 (39.2%) | 28 (45.2%) | 14 (31.1%) | ||
| Response | |||||
| CR | 9 (8.4%) | 7 (11.3%) | 2 (4.4%) | 7.488 | 0.112 b |
| PR | 72 (67.3%) | 45 (72.6%) | 27 (60.0%) | ||
| SD | 7 (6.5%) | 4 (6.4%) | 3 (6.7%) | ||
| PD | 19 (17.8%) | 6 (9.7%) | 13 (28.9%) | ||
a
DCF, docetaxel, cisplatin, and fluorouracil and other fluoropyrimidine-based adjuvant chemotherapy; ECF, epirubicin, cisplatin, and fluorouracil; FOLFOX, folinic acid, oxaliplatin, and fluorouracil; TCF, paclitaxel, cisplatin, and fluorouracil; TF, docetaxel and fluorouracil; TS, paclitaxel and S-1.
b
Performed using the Fisher’s exact test.